It wonâ€™t be up to us to seek approval for the drug," Mr. Wilkinson said in the interview, which took place at his hotel on a rundown block in San Francisco, where he was pitching the company to potential buyers at the JPMorgan Health Care Conference. Like many biotech   Innate has had ups and downs, Mr. Wilkinson said. " But sometimes, things happen," he added. 